Market closedNon-fractional
MediciNova/MNOV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About MediciNova
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Ticker
MNOV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
La Jolla, United States
Employees
13
Website
www.medicinova.com
MediciNova Metrics
BasicAdvanced
$69M
Market cap
-
P/E ratio
-$0.17
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$69M
Beta
0.72
Financial strength
Current ratio
19.065
Quick ratio
18.777
Long term debt to equity
0.587
Total debt to equity
0.951
Management effectiveness
Return on assets (TTM)
-9.39%
Return on equity (TTM)
-13.18%
Valuation
Price to revenue (TTM)
69.158
Price to book
1.16
Price to tangible book (TTM)
1.52
Price to free cash flow (TTM)
-8.492
Growth
Earnings per share change (TTM)
-38.77%
3-year revenue growth
-37.00%
3-year earnings per share growth
-11.82%
What the Analysts think about MediciNova
Analyst Ratings
Majority rating from 1 analysts.
MediciNova Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$2.7M
35.00%
Profit margin
0.00%
NaN%
MediciNova Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.06
-$0.01
-$0.04
-$0.06
-
Expected
-$0.07
-$0.08
-$0.08
-$0.05
-$0.06
Surprise
-14.29%
-87.50%
-50.00%
20.00%
-
MediciNova News
AllArticlesVideos
MediciNova Chief Business Officer David H. Crean, Ph.D.
GlobeNewsWire·2 weeks ago
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
GlobeNewsWire·1 month ago
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MediciNova stock?
MediciNova (MNOV) has a market cap of $69M as of July 06, 2024.
What is the P/E ratio for MediciNova stock?
The price to earnings (P/E) ratio for MediciNova (MNOV) stock is 0 as of July 06, 2024.
Does MediciNova stock pay dividends?
No, MediciNova (MNOV) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next MediciNova dividend payment date?
MediciNova (MNOV) stock does not pay dividends to its shareholders.
What is the beta indicator for MediciNova?
MediciNova (MNOV) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell MediciNova stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.